Justin Petrone

Ibex announced earlier this month that it had secured several contracts to offer Galen Prostate and Galen Breast to 25 UK National Health Service trusts.

DNADX will be launched as an RUO test while the firm continues to work toward setting up a US laboratory.

The Belfast, Northern Ireland-based company also believes its technology could be used to create other early-stage detection tests for multiple cancers.

The British company aims to combine the digital pathology and radiology data with its whole-genome sequencing dataset to create a new multimodal research platform.

InDx 2.0 is being supported by the Bangalore Life Sciences Cluster, the Rockefeller Foundation, the Bill & Melinda Gates Foundation, and FIND.

The researchers have been developing supramolecular assays based on chemiluminescent chemosensors that can detect metabolites in saliva, blood, and urine.

The white paper, called A Strategic Technology Roadmap for the UK In Vitro Diagnostics Industry, was funded by Innovate UK, the UK's national innovation agency.

The grant was recently awarded through the EU's Cancer Mission, a funding program to reduce cancer cases throughout the EU by 2030.

A shortage of regulatory capacity continues to slow the implementation of the EU's In Vitro Diagnostic Regulation.

The project, called PCR-4-All, officially commenced Dec. 1 and will run through November 2026.